Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
published in: The Lancet
date of publication: 2016-12-05
language: English
main subject: phase III clinical trial, placebo, hepatocellular carcinoma
Cites articles 28
Date
Title
Article - wd:Q38785510